1. Home
  2. HOWL

HOWL

Werewolf Therapeutics Inc.

Logo Werewolf Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Founded: 2017 Country:
United States
United States
Employees: N/A City: WATERTOWN
Market Cap: 200.4M IPO Year: 2021
Target Price: $10.86 AVG Volume (30 days): 237.8K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.05 EPS Growth: N/A
52 Week Low/High: $1.57 - $8.19 Next Earning Date: 05-09-2024
Revenue: $19,943,000 Revenue Growth: 21.60%
Revenue Growth (this year): -70.18% Revenue Growth (next year): 165.38%

Share on Social Networks: